RNA and Protein Degrader/Modulator Modalities of Small Molecules
In the evolving landscape of drug discovery, RNA and protein degrader/modulator modalities have emerged as revolutionary approaches in small-molecule therapeutics. These cutting-edge strategies offer a pathway to tackle previously “undruggable” targets and expand therapeutic horizons across multiple disease areas.
At Aragen Life Sciences, we empower innovation in Integrated Drug Discovery (IDD) by advancing cutting-edge RNA and protein degrader/modulator platforms. Our expertise transforms challenging drug targets into therapeutic realities, enabling breakthroughs across oncology, CNS disorders, inflammation, metabolic diseases, and more.
RNA-Targeting Small Molecules
Small molecules targeting RNA are reshaping the therapeutic landscape by modulating gene expression at its source. These molecules can:
Applications span oncology, rare genetic disorders, metabolic diseases, and infectious diseases, offering precision intervention at the molecular level.
Protein Degraders and Modulators
Protein degraders, such as PROTACs (Proteolysis Targeting Chimeras) and molecular glues, have transformed how we approach challenging targets by harnessing the cell’s natural degradation machinery. These approaches:
Our capabilities encompass rational design, synthesis, and screening of small molecules that exploit these mechanisms, ensuring robust discovery and development pipelines.
Comprehensive Support for Next-Generation Modalities
As a Contract Research Organization (CRO), we offer end-to-end support in RNA and protein degrader/modulator development, including:
Partner with us to pioneer transformative therapies in RNA and protein modulation. Let’s redefine the boundaries of small-molecule drug discovery together.
